Disposition of 7453 shares by Silverman Peter B. of Merus BV at 17.94 subject to Rule 16b-3
MRUS Stock | USD 45.53 1.13 2.55% |
Slightly above 57% of all Merus BV's private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Merus BV suggests that some traders are interested. Merus BV's investing sentiment can be driven by a variety of factors including economic data, Merus BV's earnings reports, geopolitical events, and overall market trends.
Merus |
Filed transaction by Merus BV Officer: Coo & Gc. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
Merus BV's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Merus BV's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Merus BV Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Merus BV can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Merus BV Historical Investor Sentiment
Investor biases related to Merus BV's public news can be used to forecast risks associated with an investment in Merus. The trend in average sentiment can be used to explain how an investor holding Merus can time the market purely based on public headlines and social activities around Merus BV. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Merus BV's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Merus BV and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Merus BV news discussions. The higher the estimate score, the more favorable the investor's outlook on Merus BV.
Merus BV Maximum Pain Price Across April 17th 2025 Option Contracts
Merus BV's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Merus BV close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Merus BV's options.
Merus BV Fundamental Analysis
We analyze Merus BV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Merus BV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Merus BV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Merus BV is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Merus BV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Merus BV stock to make a market-neutral strategy. Peer analysis of Merus BV could also be used in its relative valuation, which is a method of valuing Merus BV by comparing valuation metrics with similar companies.
Peers
Merus BV Related Equities
MLYS | Mineralys Therapeutics, | 10.50 | ||||
LYEL | Lyell Immunopharma | 6.06 | ||||
PTGX | Protagonist Therapeutics | 3.02 | ||||
SNDX | Syndax Pharmaceuticals | 2.17 | ||||
LRMR | Larimar Therapeutics | 0.68 | ||||
PCVX | Vaxcyte | 0.88 | ||||
REPL | Replimune | 0.88 | ||||
ANAB | AnaptysBio | 1.11 | ||||
INBX | Inhibrx | 1.12 | ||||
KURA | Kura Oncology | 1.40 | ||||
ADAG | Adagene | 1.49 | ||||
ANEB | Anebulo Pharmaceuticals | 1.60 | ||||
KRON | Kronos Bio | 2.00 | ||||
STRO | Sutro Biopharma | 2.42 | ||||
ACRV | Acrivon Therapeutics, | 3.98 | ||||
CRNX | Crinetics Pharmaceuticals | 6.70 |
Additional Tools for Merus Stock Analysis
When running Merus BV's price analysis, check to measure Merus BV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merus BV is operating at the current time. Most of Merus BV's value examination focuses on studying past and present price action to predict the probability of Merus BV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merus BV's price. Additionally, you may evaluate how the addition of Merus BV to your portfolios can decrease your overall portfolio volatility.